Need Help?

Pediatric Low-Grade Glioma RNA and Targeted Sequencing

Pediatric low-grade gliomas (pLGG) are frequently driven by genetic alterations in the RAS/MAPK pathway yet show unexplained variability in their clinical outcome. To address this, we characterized a cohort of >1,000 clinically annotated pLGG. 84% of cases harbored a driver alteration, while those without an identified alteration also often exhibited up-regulation of the RAS/MAPK pathway. pLGG could be broadly classified based on their alteration type. Rearrangement-driven tumors were diagnosed at a younger age, enriched for WHO grade I histology, infrequently progressed, and rarely resulted in death as compared to SNV-driven tumors. Further sub-classification of clinical-molecular correlates stratified pLGG into risk categories. These data highlight the biological and clinical differences between pLGG subtypes and opens avenues for future treatment refinement.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001005987 Illumina HiSeq 2500 Illumina MiSeq 101
Publications Citations
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas.
Cancer Cell 37: 2020 569-583.e5
196
Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment.
Nat Commun 15: 2024 5790
1